Folliculin inhibitors belong to a distinct chemical class of compounds that are specifically designed to target and interact with the protein known as folliculin.This protein, encoded by the FLCN gene, plays a crucial role in various cellular processes, particularly in the regulation of cell growth and proliferation. Folliculin is commonly found in the kidneys, lungs, and skin, where it acts as a key component of complex cellular signaling pathways. By modulating the activity of folliculin, these inhibitors can potentially influence various cellular functions. The mechanism of action of folliculin inhibitors involves the disruption of the protein's normal function, either by binding directly to the protein itself or interfering with its interactions with other cellular components. This disruption can lead to alterations in cell signaling cascades and may impact cellular processes like cell cycle regulation, nutrient sensing, and energy metabolism.
The aim of these inhibitors is to provide researchers with valuable tools to study the role of folliculin in different biological contexts and to gain a deeper understanding of its molecular functions. Researchers are exploring the potential applications of folliculin inhibitors in some studies, with a primary focus on understanding their effects on cellular processes and signaling pathways. By elucidating the precise role of folliculin, these inhibitors may contribute to the advancement of scientific knowledge in areas such as cell biology, molecular genetics, and cancer research. Despite their potential, it is essential to approach the study of folliculin inhibitors with caution, as the intricate nature of cellular processes requires comprehensive investigations to avoid any unintended consequences or off-target effects. Continued research in this field will be vital to uncover the full scope of these inhibitors' impact and their potential implications for various biological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
A dual PI3K/mTOR inhibitor that indirectly affects FLCN signaling through the mTOR pathway. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
An mTOR inhibitor with potential effects on the FLCN pathway. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
A tyrosine kinase inhibitor that has shown potential effects on FLCN pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Another tyrosine kinase inhibitor with potential implications for FLCN activity. | ||||||
Lapatinib ditosylate | 388082-78-8 | sc-202205B sc-202205 sc-202205A | 5 mg 10 mg 25 mg | $49.00 $77.00 $117.00 | 15 | |
A dual HER2 and EGFR tyrosine kinase inhibitor, which may indirectly impact FLCN signaling. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
A chemotherapy drug that has been investigated for its effects on FLCN-mutated kidney cancer cells. | ||||||